{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:43:32Z","timestamp":1780926212852,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ctrv.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T11:30:50Z","timestamp":1500463850000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review"],"prefix":"10.1016","volume":"59","author":[{"given":"Paola","family":"Queirolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ctrv.2017.07.002_b0005","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2017.07.002_b0010","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA group. preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctrv.2017.07.002_b0015","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. [updated March 2011] The Cochrane Collaboration; 2011."},{"issue":"10","key":"10.1016\/j.ctrv.2017.07.002_b0020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving Nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2017.07.002_b0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus Ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.07.002_b0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2017.07.002_b0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"9948","key":"10.1016\/j.ctrv.2017.07.002_b0040","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"The Lancet"},{"issue":"15","key":"10.1016\/j.ctrv.2017.07.002_b0045","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.ctrv.2017.07.002_b0050","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.07.002_b0055","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.ctrv.2017.07.002_b0060","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2017.07.002_b0065","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2017.07.002_b0070","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2017.07.002_b0075","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2017.07.002_b0080","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.07.002_b0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.07.002_b0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2017.07.002_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ctrv.2017.07.002_b0100","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2017.07.002_b0105","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (Anti\u2013Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2017.07.002_b0110","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2017.07.002_b0115","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2017.07.002_b0120","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2017.07.002_b0125","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.07.002_b0130","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw416","article-title":"Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study","author":"Kanda","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.07.002_b0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.07.002_b0140","doi-asserted-by":"crossref","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, Majem M, Fidler MJ, de Castro Jr G et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. http:\/\/dx.doi.org\/10.1016\/S0140-6736(15)01281-7.","DOI":"10.1016\/S0140-6736(15)01281-7"},{"issue":"17","key":"10.1016\/j.ctrv.2017.07.002_b0145","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2017.07.002_b0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2017.07.002_b0155","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2017.07.002_b0160","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2017.07.002_b0165","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2017.07.002_b0170","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2017.07.002_b0175","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial","volume":"2","author":"George","year":"2016","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2017.07.002_b0180","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2017.07.002_b0185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2017.07.002_b0190","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2017.07.002_b0195","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2017.07.002_b0200","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2017.07.002_b0205","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2017.07.002_b0210","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ctrv.2017.07.002_b0215","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2017.07.002_b0220","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2017.07.002_b0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2017.07.002_b0230","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.ctrv.2017.07.002_b0235","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti\u2013PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2017.07.002_b0240","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ctrv.2017.07.002_b0245","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2017.07.002_b0250","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1158\/1078-0432.CCR-14-3128","article-title":"CCR 20th anniversary commentary: immune-related response criteria\u2014capturing clinical activity in immuno-oncology","volume":"21","author":"Hoos","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.07.002_b0255","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"Vries EG; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721730107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721730107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:22:18Z","timestamp":1535588538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721730107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":51,"alternative-id":["S030573721730107X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.07.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}